Literature DB >> 32460399

Genetic variants in the MTHFR are not associated with fatty liver disease.

Antonio De Vincentis1, Rosellina Margherita Mancina2, Jussi Pihlajamäki3,4, Ville Männistö5,6, Salvatore Petta7, Paola Dongiovanni8, Anna Ludovica Fracanzani8,9, Luca Valenti9,10, Federica Tavaglione1,2, Stefano Romeo2,11,12, Umberto Vespasiani-Gentilucci1.   

Abstract

The common missense sequence variants of methylenetetrahydrofolate reductase (MTHFR), rs1801131 (c.A1298C) and rs1801133 (c.C677T), favour the development of hyperhomocysteinemia and diminished DNA methylation. Previous studies, carried out in small series and with suboptimal characterization of the hepatic phenotype, tested the association of these genetic variants with fatty liver disease (FLD), with conflicting results. Here, we assessed the association of rs1801131 and rs1801133 with hepatic phenotype in the Liver Biopsy Cross-Sectional Cohort, a large cohort (n=1375 from Italy and 411 from Finland) of European individuals with suspect FLD associated with dysmetabolism. A total of 1786 subjects were analysed by ordinal regression analyses. The rs1801131 and the rs1801133 variants were not associated with steatosis, inflammation, ballooning or fibrosis. The present study suggests that changes in folate and methionine metabolism resulting from these 2 variants are not associated with a clinically significant impact on FLD in Europeans.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  MTHFR; NAFLD; NASH; fatty liver disease; fibrosis; steatosis

Mesh:

Substances:

Year:  2020        PMID: 32460399     DOI: 10.1111/liv.14543

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  1 in total

1.  Metabolic and genetic determinants for progression to severe liver disease in subjects with obesity from the UK Biobank.

Authors:  Stefano Romeo; Umberto Vespasiani-Gentilucci; Antonio De Vincentis; Federica Tavaglione; Rocco Spagnuolo; Roberta Pujia; Dario Tuccinardi; Gianluca Mascianà; Antonio Picardi; Raffaele Antonelli Incalzi; Luca Valenti
Journal:  Int J Obes (Lond)       Date:  2021-11-08       Impact factor: 5.551

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.